We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by Novartis

News   Mar 23, 2018 | Original story from The Wyss Institute

 
Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by Novartis

Made of the polymer that’s used in biodegradable sutures, this aspirin-sized device is designed to deliver immunotherapy agents that activate the immune system against tumors. Image courtesy of the Wyss Institute at Harvard University

 
 
 

RELATED ARTICLES

“Minerva” – The Roman Goddess Involved in Metastasis

News

Researchers have identified a new gene in the fruit fly Drosophila that is required for regulating the addition of T-antigen onto a subset of proteins in immune cells.

READ MORE

Protein "Spat Out" by Cancer Cells Promotes Tumor Growth

News

Prostate cancer cells change the behavior of other cells around them, including normal cells, by 'spitting out' a protein from their nucleus.

READ MORE

Chemical Found in Charred Foods Linked to Cancer Development

News

A tumour-specific mutation spectrum can be introduced into the genome by glycidamide, a metabolite of acrylamide that people are commonly exposed to in charred foods as well as tobacco smoke.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE